LEXINGTON, Mass., Oct. 18, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a developer of therapeutic vaccines for cancer and infectious diseases, today announced that the company will be presenting at the NewsMakers in the Biotech Industry Conference on Friday, October 21st at the Millennium Broadway Hotel & Conference Center in New York City.
Dr. Garo Armen, Chairman and CEO of Agenus, will present a corporate overview from 11:30 am-11:55 am in Room 311.
Between Agenus and its partners, 18 programs are in clinical development. Agenus' QS-21 Stimulon® adjuvant* is being studied in clinical trials for 15 vaccine indications. They include:
- Phase 3: GSK's RTS,S for malaria
- Phase 3: GSK's MAGE-A3 for non-small cell lung cancer
- Phase 3: GSK's MAGE-A3 for melanoma
- Phase 3: GSK's Zoster Herpes for shingles
- Phase 2: Janssen's** ACC-001 for Alzheimer's disease
Agenus' pipeline programs include:
- Phase 2: Prophage Series G-100 for newly diagnosed glioma
- Phase 2: Prophage Series G-200 for recurrent glioma
- Phase 2-Ready: HerpV (contains QS-21 Stimulon) for genital herpes
The live and archived webcast of the company presentation will be accessible from the company's website at www.agenusbio.com/webcast. Please log in approximately 5-10 minutes before each event to ensure a timely connection. The archived replay will be available on the Agenus website for one month following the conference.
About Agenus
Agenus Inc. is a biotechnology company working to develop treatments for cancers and infectious diseases. The company is focused on immunotherapeutic products based on strong platform technologies with multiple product candidates advancing through the clinic, including several product candidates that have advanced into late-stage clinical trials through corporate partners. For more information, please visit www.agenusbio.com.
The Agenus logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8187
Forward-Looking Statement
This press release contains forward-looking statements, including statements regarding up-coming presentations and the clinical development programs of the company and its licensees. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission for the period ended June 30, 2011. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this document, and Agenus undertakes no obligation to update or revise the statements. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Agenus' business is subject to substantial risks and uncertainties, including those identified above. When evaluating Agenus' business and securities, investors should give careful consideration to these risks and uncertainties.
*QS-21 Stimulon® adjuvant is an asset of Antigenics, Inc., a wholly owned subsidiary of Agenus Inc.
**Janssen Alzheimer Immunotherapy, a wholly owned subsidiary of Johnson & Johnson.
Stimulon is a registered trademark of Agenus Inc. and its subsidiaries.